Mobile immunotherapy with chimeric antigen receptor (CAR)-T cells (CARTs) represents a breakthrough within the therapy of hematologic malignancies. CARTs are genetically engineered hybrid receptors that
![Immunology and Cancer Biology University of California](https://teitell-lab.com/hf/uploads/2021/04/teitell_lab_header.gif)
Immunology and Cancer Biology University of California
Apoptosis, flow, mitochrondria, FITC, cytoplasmic membrane, oncoprotein